Waitlists for Quebec specialists have nearly one million patients as system struggles to keep up
The number of Quebecers waiting to see a medical specialist has nearly doubled in the past five years, with more than 900,000 people now on a growing waitlist that health officials admit is spiraling out of control.
'I feel for the patients, mostly. And I think that's what all doctors feel, which is we'd love to see those patients,' said Dr. Rafik Ghali of the Federation of Quebec Medical Specialists.
He explained that when a request for a consultation is submitted, the patient's condition is graded by priority. Each grade has a maximum delay before the patient must be seen, which can range from three days to up to a year.
Out of the more than 900,000 currently on a waitlist, nearly two-thirds have seen their deadline come and go.
'Those are patients who have minor ailments. You can wait three months or a year. Unfortunately, that usually means you can wait a little longer,' Ghali added.
Santé Québec said there are many reasons for the growing waitlist, including an aging population, which means more patients with more complicated cases.
Additionally, the agency said there aren't enough specialists available.
Ghali noted that with budget cuts and shorter clinic hours, the system is unable to meet the demand.
'We're still seeing a lot of patients. What the medical specialists want to do is see the patients that are there. But it has become untenable,' he said.
Paul Brunet, a patient's rights advocate with the Council for the Protection of Patients, said some quick fixes could be put in place now.
'A lot of specialists have gone private, and one of the solutions that apparently works in Ontario is that you fix, by law, the rate — would it be private or public — so that we could use private specialists at the same rate to help us out,' Brunet said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
20 hours ago
- National Post
Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops
Article content Phase 3 data show Bausch + Lomb's LUMIFY Preservative Free eye drops are as safe and effective as the original LUMIFY in reducing ocular redness The multicenter study with 380 participants confirmed that LUMIFY Preservative Free eye drops are non-inferior in efficacy to the original LUMIFY and have a favorable safety profile, offering an effective preservative-free option for sensitive eyes LUMIFY delivers noticeable results in one minute, lasts up to eight hours and is the No. 1 doctor-recommended redness reliever brand; more info at Article content VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Ophthalmology and Therapy has published results from a phase 3 study which assessed the efficacy and safety of LUMIFY Preservative Free redness reliever eye drops compared to LUMIFY redness reliever eye drops for reducing ocular redness. Article content 'Since launching in 2018, LUMIFY has been the No. 1 doctor-recommended redness reliever brand, known for delivering noticeable results in one minute and lasting up to eight hours,' 1 said John Ferris, president, Consumer, Bausch + Lomb. 'This study demonstrates that our new LUMIFY Preservative Free eye drops reduce redness quickly and are just as safe and effective as the original LUMIFY, providing a needed option for patients with eye sensitivities.' Article content In the randomized, active-controlled, multicenter study, 380 participants with ocular redness received either LUMIFY Preservative Free or LUMIFY, administered as a single drop four times daily for four weeks. The primary objective was to demonstrate that LUMIFY Preservative Free is non-inferior to LUMIFY in reducing ocular redness. The primary efficacy endpoint was investigator-assessed ocular redness score at eight timepoints from five-minutes to 240-minutes after drop administration on day one. The secondary objective of the study was to compare the safety of LUMIFY Preservative Free and LUMIFY. Article content The study met its primary objective, confirming that LUMIFY Preservative Free is statistically non-inferior to LUMIFY in reducing ocular redness in adults. A day one analysis of all 11 time points (one minute to 480 minutes post-administration) further supported these findings; and additional secondary efficacy endpoint data from one minute, 360 minutes and 480 minutes post-administration demonstrated that LUMIFY Preservative Free performs similarly to LUMIFY. The overall safety profile of LUMIFY Preservative Free was favorable and comparable to LUMIFY, and the occurrence of ocular treatment-emergent adverse events was similar in both treatment groups. In this clinical trial, LUMIFY Preservative Free demonstrated to have a low incidence of side effects, like rebound redness and loss of efficacy over time, when used as directed. Article content 'The results show that LUMIFY Preservative Free is a well-tolerated alternative option for consumers with ocular redness who have sensitivities to preservatives or are at increased risk of ocular surface disease,' said Melissa Toyos, MD, and partner, Toyos Clinic, Nashville, TN. Article content About the LUMIFY Brand Article content The LUMIFY brand began in 2018 with the U.S. launch of LUMIFY redness reliever eye drops. Before LUMIFY, redness relievers relied on the same ingredients for decades and were associated with well-known side effects. LUMIFY and LUMIFY Preservative Free are the only over-the-counter redness relievers formulated with low-dose brimonidine tartrate 0.025% that selectively target eye redness and offer excellent results with a lower risk of rebound redness and loss of efficacy when used as directed. In 2023, Bausch + Lomb introduced LUMIFY EYE ILLUMINATIONS™, a line of specialty eye care products specifically developed for the sensitive area around the eyes. In June 2025, Bausch + Lomb launched LUMIFY Preservative Free eye drops in the U.S. For more information on the LUMIFY brand, visit Article content Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit Article content Facebook Article content , Article content Instagram Article content , Article content LinkedIn Article content , Article content X Article content and Article content YouTube Article content . Article content References Article content ©2025 Bausch + Lomb. Article content Article content Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Kristy Marks Article content Article content Article content
CTV News
20 hours ago
- CTV News
UnitedHealth falls short of second quarter expectations and offers weak outlook for 2025
The logo for UnitedHealth Group appears above a trading post on the floor of the New York Stock Exchange, April 17, 2025. (AP Photo/Richard Drew, file) UnitedHealth delivered disappointing second-quarter earnings and went conservative with its 2025 forecast as soaring medical costs continue to swamp insurers. The health care giant said Tuesday expenses that have jumped beyond what it expected when it set coverage prices will continue to pressure its performance. But the company expects a return to earnings growth in 2026. UnitedHealth now expects adjusted earnings of at least $16 per share in 2025 after withdrawing its previous forecast in May. It had started 2025 with expectations of making up to $30 per share. For the full year, analysts forecast earnings of $20.64 per share, according to the data firm FactSet. UnitedHealth Group Inc. runs one of the nation's largest health insurance and pharmacy benefits management businesses. The Eden Prairie, Minnesota, company also operates a growing Optum business that provides care and technology support. In May, the company withdrew its 2025 forecast due to higher-than-expected medical costs, and CEO Andrew Witty departed the company abruptly. He was replaced by Chairman Stephen Hemsley, who was the UnitedHealth CEO for more than a decade until 2017. That came after the company took the rare step in April of cutting its forecast. That pushed UnitedHealth shares down $130 in its worst single-day performance in over 25 years. Hemsley promised in June that UnitedHealth would establish a 'prudent' 2025 earnings outlook when it detailed second-quarter results. He also said the company had underestimated care activity and cost trends, but improvements were being made. In the second quarter, UnitedHealth reported adjusted earnings of $4.08 per share on $111.6 billion in total revenue. Analysts expected earnings of $4.48 per share on $111.5 billion in revenue, according to FactSet. The company's profit fell 19% to $3.41 billion even as revenue rose 13%. Medical costs, the company's biggest operating expense, jumped 20% to $78.6 billion in the quarter. UnitedHealth is normally the first insurer to report earnings every quarter. But this summer, it followed competitors like Elevance Health Inc. and Centene Corp. that have lowered their annual forecasts and delivered disappointing results. Several insurers say they have been hit by medical costs that are growing faster than expected. Companies have seen a rise in expensive emergency rooms visits and growing prescription drug costs, especially from expensive cancer treatments and gene therapy. They've also seen a rise in behavioral health care, which includes the treatment of mental health conditions and substance use disorders. UnitedHealth shares slid about more than 3% to $272.30 before the opening bell Tuesday. That price topped $630 last November to reach a new all-time high. But the stock has mostly shed value since December, when UnitedHealthcare CEO Brian Thompson was fatally shot in midtown Manhattan on his way to the company's annual investor meeting. Shares are down 44% so far this year. The Dow Jones Industrial Average, of which UnitedHealth is a member, has climbed 5%. Tom Murphy, The Associated Press
Globe and Mail
20 hours ago
- Globe and Mail
Eli Lilly and Loxo Oncology's Promising Study on Pirtobrutinib for CLL/SLL
(LLY)), Loxo Oncology Inc ((LOXO)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Eli Lilly and Company, in collaboration with Loxo Oncology Inc., is conducting a Phase 3 study titled 'A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)'. The study aims to evaluate the efficacy and safety of the experimental drug Pirtobrutinib compared to the standard treatment of Bendamustine plus Rituximab in patients who have not received prior treatment for CLL/SLL. The study tests two interventions: Pirtobrutinib, an oral medication, and a combination of Bendamustine and Rituximab, administered intravenously. Pirtobrutinib is being evaluated for its potential to offer a more effective and safer treatment option. This interventional study is randomized with a parallel assignment model. Participants are divided equally into two groups, with no masking involved. The primary purpose is treatment, allowing crossover for patients with disease progression. The study began on September 23, 2021, with an active but not recruiting status. The last update was submitted on July 22, 2025, indicating ongoing progress. These dates are crucial for tracking the study's development and anticipated results. The outcome of this study could significantly impact Eli Lilly's and Loxo Oncology's stock performance by potentially introducing a new treatment option in the CLL/SLL market. This could influence investor sentiment positively, especially if Pirtobrutinib proves to be a superior treatment. Competitors in the oncology space will be closely monitoring these developments. The study remains active, with further details available on the ClinicalTrials portal.
